Suppression of EZH2 expression in CD4+ T cells might be mediating at least some of the therapeutic effects observed with blocking mTOR activation and with glycolysis inhibitors in SLE and lupus-prone animal models. Here, CD4 is linked to systemic lupus erythematosus.